Organon Settles Remeron Antitrust Cases; Injunction Follows Bristol Model
Executive Summary
The proposed settlement of a patent listing case against Organon follows the model of the injunction negotiated by Bristol-Myers Squibb and the Federal Trade Commission a year ago